PD-L1/ITGB4 Axis Modulates Sensitivity of Hepatocellular Carcinoma to Sorafenib via FAK/AKT/mTOR Signaling Pathway
The PD-L1/ITGB4 axis drives sorafenib resistance via FAK/AKT/mTOR hyperactivation. Dual targeting of PD-L1/ITGB4 enhances sorafenib efficacy, revealing a tumor-intrinsic mechanism and proposing a novel combinatorial strategy for HCC.
Authors
- Zengli Wang (ORCID: https://orcid.org/0000-0002-1447-6689)
- Niandie Cao
- Yong Liang (ORCID: https://orcid.org/0000-0003-3679-3084)
- Zhu Tao
- Shuping Zhou (ORCID: https://orcid.org/0000-0003-1220-3019)
- Xiaolong Tang (ORCID: https://orcid.org/0000-0001-8431-8080)
- Song Ouyang (ORCID: https://orcid.org/0000-0002-4260-3163)
- Li Tu (ORCID: https://orcid.org/0000-0003-3307-5554)
Institutions
- Xuzhou Medical College (CN)
- Anhui University of Science and Technology (CN)
- Second People’s Hospital of Huai’an (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/itt.s534782
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64